The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

Insomnia often causes excessive daytime sleepiness and fatigue. Obstructive sleep apnea (OSA) is when you briefly stop breathing during sleep because the airways of your throat become too narrow ...

The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) are 2 screening tools that are regularly used in clinical practice. Although these tests are commonly used to detect ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

Evaluation of potential screening tools PSG was abnormal in 11 children ... values are found with screening by oximetry for obstructive sleep apnea in children. 5 “Unlike the current SMA ...

Short sleepers cruise by on four to six hours a night and don’t seem to suffer ill effects Marla Broadfoot, Knowable Magazine Some people are genetically built to require less sleep than the ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug ...

US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for the condition that affects millions of Americans. "This is a major step ...

The US Food and Drug Administration (FDA) has approved the obesity treatment tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.